Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Convertible Debt: 2022-2023

  • SAB Biotherapeutics' Convertible Debt was N/A to $541,644 in Q2 2023 from the same period last year, while for Jun 2023 it was $541,644, marking a year-over-year change of. This contributed to the annual value of $541,644 for FY2022, which is N/A change from last year.
  • According to the latest figures from Q2 2023, SAB Biotherapeutics' Convertible Debt is $541,644, which was down 0.00% from $541,644 recorded in Q1 2023.
  • In the past 5 years, SAB Biotherapeutics' Convertible Debt ranged from a high of $541,644 in Q4 2022 and a low of $541,644 during Q4 2022.
  • In the last 2 years, SAB Biotherapeutics' Convertible Debt had a median value of $541,644 in 2023 and averaged $541,644.